ISRCTN14084351已完成3 期
A multi-centre, randomized, double-masked, placebo-controlled, parallel-group, phase III study to assess efficacy and safety of Bibrocathol 2% eye ointment (Bibrocathol-POS 2%) in the treatment of chronic blepharoconjunctivitis
RSAPHARM Arzneimittel GmbH0 个研究点目标入组 200 人开始时间: 2021年3月8日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 200
研究概览
简要总结
2022 Results article in https://doi.org/10.17352/2455-1414.000096 (added 09/09/2022)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Written informed consent
- •2. Ambulatory male and female patients =18 years of age
- •3. Diagnosis of chronic blepharoconjunctivitis
- •4. A summarised score of signs and symptoms (sum score of severity of lid oedema, lid erythema, debris, hyperemia and pouting of Meibomian glands and additionally the patient’s assessment of ocular discomfort) of = 18 at baseline
- •5. Ability of the patient to cooperate (able to understand the provided information about the clinical trial, willing to comply with the requirements of the study protocol)
- •6. Consent to use adequate contraception
- •7. Women using adequate contraception with a negative pregnancy test (for women with childbearing potential), or women who had menopause 2 years before the start of the study or earlier
排除标准
- •Non-inclusion criteria:
- •Ocular conditions:
- •1. Chronic blepharoconjunctivitis requiring antibiotic treatment
- •2. Therapy-resistant chronic blepharoconjunctivitis
- •3. Acute ocular and/or follicle or lid infection or active ocular inflammation other than blepharoconjunctivitis
- •4. Irritations of the outer eye that are related to corneal damage (e. g. erosions, injuries, burns)
- •5. Abnormal eyelid anatomy (other than due to chronic blepharoconjunctivitis)
- •6. Ocular surgery within 90 days (trauma, intraocular surgery, refractive surgery, palpebral surgery (e.g. ectopium OP), etc)
- •7. Severe dry eye syndrome also due to systemic diseases
- •8. Allergic eye disease
- •9. Glaucoma
- •10. IOP =21 mmHg (non-contact tonometry)
- •11. Patients with only one eye
- •Systemic condition:
- •12. Known hypersensitivity to the investigational product or any of the ingredients from the composition of the investigational product (or of placebo)
- •13. Severe systemic disease (incl. rheumatoid arthritis, ankylosing spondylitis)
- •14. Subjects with a history of malignancy of any organ system, treated or untreated, within the past 5 years, whether or not evidence of local recurrence or metastases exists
- •Concomitant medication:
- •15. Oral or topical antibiotics 2 weeks prior to and during the trial
- •16. Any other ocular antiseptics during the trial
- •17. Topical ocular or systemic corticosteroids 2 weeks prior to and during the trial (except chronic use of inhalative corticosteroids if on stable dose 1 month prior to and during the trial)
- •18. Topical ocular and systemic NSAIDs 2 weeks prior to and during the trial (low-dose oral acetylsalicylic acid and occasional use of painkillers is allowed)
- •19. Local ocular use of antihistamines 1 month and prior to and during the trial
- •20. Ocular a-sympathomimetics 1 month and prior to and during the trial
- •21. Patients who anticipate changes in their ongoing regimen of concurrent systemic therapies that could affect trial parameters
- •22. Pregnant or breastfeeding women
- •23. Women with childbearing potential, not using a reliable and medically accepted method of contraception (no pregnancy test is required in women, being 2 years after menopause)
- •24. Any systemic or ocular medical or physical condition which, in the investigator’s opinion, would preclude the participant from adhering to the protocol or completing the trial per protocol
- •25. Patients participating in another clinical trial at the same time
- •26. Patients taking any investigational product during the last 28 days
- •27. Patients already once included in this trial
- •1. Recall of the informed consent by the patient
- •2. Necessity to discontinue study treatment /placebo due to the occurrence of adverse events and/or exacerbation of concurrent diseases which prevent further participation in the study
- •3. Applicability of adjunctive therapy which is not permitted within this Protocol
- •4. Other con
研究者
相似试验
已完成
不适用
Evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage.Topic: Injuries and Emergencies, HaematologySubtopic: Injuries and Emergencies (All Subtopics), Haematology (All Subtopics)Disease: Injuries and Emergencies, Non-malignant HaematologyInjury, Occupational Diseases, PoisoningISRCTN67540073HS Blood and Transplant (NHSBT)48
已完成
3 期
Clinical study to assess the efficacy and safety of Silexan in patients with depressioMild to moderate major depressive episodeMental and Behavioural DisordersISRCTN36202964Dr Willmar Schwabe (Germany)577
已完成
不适用
Managing Avascular Necrosis Treatments: an Investigational Study (MANTIS)Avascular necrosis of the hipMusculoskeletal DiseasesOsteonecrosisISRCTN14015902niversity of Oxford21
已完成
2 期
Repurposing anti-TNF for treating Dupuytren’s diseaseDupuytren's disease of the handSkin and Connective Tissue DiseasesDupuytren's diseaseISRCTN27786905niversity of Oxford181
已完成
3 期
Study of mirtazapine for agitation in dementiaISRCTN17411897niversity of Sussex247